SCHEMBL2164263

SCHEMBL2164263

N#Cc1c(F)cccc1OCC1CCC(Cc2cccc(Cl)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DHFR P00374 1/20 0.39
SLC6A4 P31645 2/20 0.38
GRM2 Q14416 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KDM2B Q8NHM5 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.35
ADRA1D P25100 1/20 0.35
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12404096 0.87 TSHR (0.41) KDM4EALDH1A1GAAATML3MBTL1
SCHEMBL1154384 0.84 KDM4E (0.46) KDM4EALDH1A1GRM2
SCHEMBL2164306 0.81 HSD11B1 (0.41) KDM4EGRM2
SCHEMBL1154362 0.80 NPC1 (0.52) DHFRSLC6A4NPC1RAB9AMRGPRX4
SCHEMBL2164341 0.80 RIPK1 (0.44) KDM4EMAPTHTTATMSLC6A4
SCHEMBL2164302 0.79 GRM2 (0.42) KDM4EGRM2NPC1RAB9A
SCHEMBL1154568 0.79 MCHR1 (0.45) KDM4E
SCHEMBL1154431 0.79 MCHR1 (0.45) KDM4E
SCHEMBL30175284 0.79 MCHR1 (0.45) KDM4E
SCHEMBL2166024 0.79 KDM4E (0.34) KDM4EALDH1A1GLAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069316-B1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2015-10-07 EP disclosed
US-7985755-B2 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-07-26 US disclosed
EP-2069316-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY Families of Spinal Muscular Atrophy (US) 2009-06-17 EP disclosed
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2009-02-12 US disclosed
WO-2008016973-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY SMN1; SMN2, MUSK, MYT1 KDM4E 548/4885ALDH1A1 1308/4885GLA 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.